Transwell assays showed that the migration and invasion capabilities of LN229 and U87-MG glioma cells transfected with RAB3D siRNA were significantly reduced when compared to those capabilities for control cells (P < 0.05, Figures 8D–G). Here, RAB3D is linked to central nervous system cancer.